Triple Reuptake Inhibitor • Coming Soon
A Different Approach to Appetite Control
Tesofensine is a novel triple monoamine reuptake inhibitor that works on serotonin, norepinephrine, and dopamine pathways—completely different from GLP-1 medications. Phase 2 trials showed up to 10.6% weight loss in 24 weeks at the highest (1.0mg) dose, with effects on both appetite suppression and resting energy expenditure. Join our waitlist to be notified when available.
10.6%
Weight Loss (1.0mg)*
24
Week Phase 2 Trial
1x
Daily Oral Dose
Not
FDA Approved
Coming Soon
A novel oral weight loss medication that works through brain neurotransmitter pathways rather than gut hormones—offering an alternative approach for patients who prefer pills over injections.
500mcg oral capsule
Potential For
Patients who prefer oral medications over injections, or those seeking an alternative mechanism to GLP-1 therapies for appetite control.
The Science
Tesofensine is a triple monoamine reuptake inhibitor—it blocks the reabsorption of serotonin, norepinephrine, and dopamine in the brain. This is a completely different mechanism from GLP-1 medications, working directly on brain neurotransmitter systems that regulate appetite, satiety, and energy expenditure.
Originally developed for Parkinson's and Alzheimer's disease, tesofensine was repurposed for obesity after clinical trials consistently showed significant weight loss as a "side effect." By modulating dopamine and serotonin pathways, it may reduce food cravings and enhance feelings of fullness while potentially increasing resting metabolic rate.
In Phase 2 trials published in The Lancet, patients lost an average of 9.2% of body weight on 0.5mg and 10.6% on 1.0mg over 24 weeks, alongside diet. In 2013 The Lancet published an expression of concern about that trial, and tesofensine is not FDA-approved.
Join the Waitlist
How It Works
Tesofensine works by blocking the reabsorption of three key neurotransmitters involved in appetite and energy regulation.
Increases serotonin availability in the brain, enhancing satiety signals and reducing cravings—similar to how SSRIs work but with additional pathways.
Boosts norepinephrine levels, potentially increasing resting energy expenditure and fat oxidation while suppressing appetite.
Modulates the reward pathway to reduce the pleasure drive for food consumption, making it easier to resist cravings and emotional eating.
Different Approaches
Tesofensine represents a fundamentally different approach to weight loss—working on brain neurotransmitters rather than gut hormones.
*Phase 2 trial data. Phase 3 trials ongoing. Not yet FDA approved.
Potential Benefits
A daily pill instead of weekly injections—ideal for patients who prefer not to self-inject or have needle aversion.
Works on brain neurotransmitter systems (serotonin, dopamine, norepinephrine) rather than gut hormones—a completely distinct pathway from GLP-1 medications.
Both suppresses appetite and potentially increases resting energy expenditure—addressing weight from both calorie intake and metabolic rate angles.
Unlike GLP-1 therapies, the primary side effects are dry mouth, headache, and insomnia rather than nausea and vomiting.
Dopamine pathway modulation may help reduce food cravings and emotional eating—addressing the psychological aspects of overeating.
Increased BDNF levels and serotonin/dopamine activity may provide mild mood-enhancing effects alongside weight loss.
What to Do Now
Tesofensine isn't available yet, but you don't have to wait to start your weight loss journey. Here's how we can help today.
Sign up to be notified when tesofensine receives FDA approval and becomes available at BHRC.
Meet with our physicians to discuss FDA-approved options like semaglutide or tirzepatide that are available now.
Begin your weight loss journey with established therapies while monitoring tesofensine's progress through approval.
When tesofensine becomes available, discuss with your physician whether its oral, neurotransmitter-based approach is right for you.
Clinical Trial Status
Tesofensine has completed Phase 2 clinical trials with Phase 3 trials ongoing. While results are promising, it has not yet received FDA approval for commercial use.
TIPO
Clinical trial program evaluating tesofensine for obesity treatment
203
Participants in the pivotal Phase 2b trial (TIPO-1)
At a glance
Your plan
Signing up means the clinic will contact you if the regulatory picture changes. It does not reserve medication, and it does not commit you to anything. Because tesofensine is investigational, there is nothing to prescribe today, and BHRC will not source it from the research or overseas market. You can leave the waitlist at any time by replying to any update or asking the front desk.
If you want to act now, the BHRC clinical team reviews your weight history, eating pattern, sleep, activity, medications and any conditions such as high blood pressure, diabetes or sleep apnea. The goal is to find an option you can actually use today and stick with. If you came in because you wanted a pill rather than an injection, say so; route preference is a legitimate factor and the provider will tell you which oral or injectable options make sense for your history.
Baseline labs and a blood pressure and heart rate reading are taken. That matters for any weight medication, and it would matter even more for a drug like tesofensine, which raised resting heart rate in its trials. Kidney and liver function, fasting glucose or HbA1c, lipids and thyroid function are also reviewed, since several common causes of weight gain show up in these tests.
Depending on your history, the provider may discuss an FDA-approved medication, a compounded GLP-1 where clinically appropriate, or a non-drug program first. The plan includes nutrition and training targets and a follow-up date. Medication doses are set individually. You will know before you leave what to expect in the first month, which side effects to report, and when your first follow-up is.
Follow-up visits track weight, waist, blood pressure and side effects. If tesofensine ever becomes an option that BHRC can lawfully prescribe, your provider will discuss whether it would add anything to the plan you are already on.
Timeline
Tesofensine is not available through BHRC. A waitlist sign-up and, if you want it, a consultation about current options.
For people who start an available medication, this is usually a period of gradual titration, side-effect management and early weight change. Results vary widely. Stomach side effects are the most common reason people stop a GLP-1 early, and they are often manageable with slower titration, so report them rather than quitting on your own.
The usual window for judging whether a weight-management plan is working, using measured weight, waist and labs.
The clinic reviews any new approval, label and safety data before deciding whether and for whom it might be offered. Nothing is promised in advance. Approval for one group of patients would not automatically make it suitable for everyone on the waitlist.
Compare
| Option | How it works | Route | Status in the US |
|---|---|---|---|
| Tesofensine | Blocks reuptake of three brain neurotransmitters | Daily oral tablet in trials | Investigational; not FDA-approved; not offered at BHRC |
| Semaglutide | GLP-1 receptor agonist; appetite and blood sugar hormones | Weekly injection (also an oral brand) | Brand products FDA-approved; compounded vials are not |
| Tirzepatide | GIP and GLP-1 receptor agonist | Weekly injection | Brand products FDA-approved; compounded vials are not |
| Nutrition, activity and sleep program | Energy balance and habit change | None | No prescription required |
Is it right for you?
Monitoring
Because BHRC does not prescribe tesofensine, there is no tesofensine monitoring protocol at the clinic. What is monitored is whichever weight-management plan you start instead: weight, waist, blood pressure and heart rate at every visit, plus repeat labs at intervals your provider sets.
The published trials tell us what would need watching if tesofensine were ever approved. In the 2008 phase 2 trial, the 0.5mg group had an average heart-rate increase of about 7 beats per minute at 24 weeks, and the most common side effects were dry mouth, nausea, constipation, diarrhea and insomnia. A smaller 2022 trial of tesofensine combined with metoprolol in hypothalamic obesity reported sleep disturbance, dry mouth and headache more often than placebo, and one participant stopped because of worsened anxiety. Any future plan would need heart-rate, blood-pressure, sleep and mood checks. The research also involved relatively short follow-up, so there is no long-term safety record to lean on.
If you have bought tesofensine online and are already taking it, tell the clinic. You will not be judged, but the provider needs to know before prescribing anything else, because combining it with other medications that affect serotonin or heart rate could be risky.
Regulatory status
Regulatory status: Tesofensine is an investigational drug. It is not approved by the FDA for any use in the United States, it does not appear in FDA's Drugs@FDA approvals database, and it is not on any category of FDA's 503A bulk drug substance list (updated May 14, 2026), so it is not covered by FDA's interim policy for compounding from bulk substances. BHRC does not prescribe, dispense or source tesofensine; the waitlist on this page is for updates only. Any weight-management treatment BHRC offers is prescribed only after a consultation with a licensed provider. This page does not claim that tesofensine is safe or effective for weight loss or any condition. Prepared by the BHRC team from FDA and PubMed sources.
Before you book
No. As of October 2026 tesofensine is not approved by the FDA for any use in the United States, and it does not appear on FDA's 503A lists of substances that compounding pharmacies may use. It is an investigational drug, which is why BHRC lists it as coming soon with a waitlist and does not prescribe it.
In a 24-week phase 2 trial published in The Lancet in 2008, adults with obesity on a calorie-reduced diet lost an average of 9.2% of body weight on 0.5mg and 10.6% on 1.0mg, compared with 2.0% on diet and placebo. A short study in 2010 found tesofensine increased feelings of fullness and fat oxidation. In 2013 The Lancet published an expression of concern about the 2008 trial, which means the journal flagged questions about the paper. Weight loss in those trials depended on diet support, and none of this research has led to an FDA approval.
In the published trials the most frequent were dry mouth, nausea, constipation, diarrhea and insomnia, plus a dose-related rise in resting heart rate. Blood pressure changes were small at lower doses but appeared at the highest dose in some studies. Long-term cardiovascular safety has not been established. Because it raises dopamine and norepinephrine activity, researchers have also watched for effects on mood, anxiety and sleep, which is consistent with the insomnia and anxiety reports in the trials.
They work in completely different ways. Tesofensine acts on brain neurotransmitters; tirzepatide and semaglutide act on gut-hormone receptors. More importantly, tirzepatide and semaglutide have large randomized trials and FDA-approved brand products, while tesofensine does not. No head-to-head trial exists, so any claim that one beats the other in weight loss is speculation. The practical difference for a patient today is simple: one can be prescribed with a known safety record and the other cannot.
Not today. BHRC does not prescribe or dispense tesofensine and will not source it from overseas or research suppliers. You can join the waitlist to be told if that changes, and you can book a consultation about available options at any time.
No. It is a small-molecule drug taken by mouth. It sits on many peptide menus because clinics group metabolic treatments together, but it is absorbed and processed like a conventional tablet, not like an injected peptide.
Because the drug is not offered here, BHRC does not set tesofensine doses. For a summary of what was used in research, see our Tesofensine Dosage Guide. It is educational only and is not an endorsement of self-sourcing.
BHRC advises against it. Products sold as tesofensine capsules or powder online are unregulated, their contents are unverified, and you would be taking a drug that raises heart rate with no medical oversight. If you already have, please tell your provider before starting anything else.
That depends on your health history. Options a BHRC provider may discuss include FDA-approved weight-management medications, compounded GLP-1 therapy where clinically appropriate, and structured nutrition and training support. Some people are better served by addressing sleep, stress or a medication that is contributing to weight gain first. Whatever you choose, the BHRC clinical team builds in follow-up so you are not left to manage side effects alone.
There is no price because there is nothing to sell. If tesofensine is ever approved, cost would depend on the approved product, insurance coverage and the monitoring it requires. Current options are quoted individually after a consultation.
Selected research
The literature below is peer-reviewed background on Tesofensine and the mechanisms discussed on this page, so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and some of it is preclinical work in animals or cells. Your provider will discuss what the evidence does and does not support for your situation.
Related peptide therapies
Questions
No, tesofensine is not yet FDA approved. It has completed Phase 2 clinical trials with Phase 3 trials ongoing. The timeline for FDA approval remains uncertain. Until approved, tesofensine is not available for commercial sale.
Tesofensine works on completely different pathways. While GLP-1 medications (semaglutide, tirzepatide) work through gut hormones and affect gastric emptying, tesofensine is a triple reuptake inhibitor that blocks reabsorption of serotonin, norepinephrine, and dopamine in the brain. It's taken as a daily oral pill rather than a weekly injection.
The most common side effects in clinical trials were dry mouth, headache, nausea, insomnia, constipation, and diarrhea. Unlike GLP-1 medications, nausea and vomiting are less prominent. Higher doses showed some increase in heart rate, which is being carefully evaluated in Phase 3 trials.
Yes, tesofensine is taken as a once-daily oral capsule—no injections required. This makes it an attractive option for patients who prefer pills over self-injection or have needle aversion.
In a Phase 2 trial, the 0.5mg dose produced about 9.2% and the 1.0mg dose about 10.6% body weight loss over 24 weeks with diet. Extended studies showed continued weight loss, with some patients losing 13-14kg over 48 weeks. Phase 3 trials will provide more definitive data.
Tesofensine is not available outside of clinical trials. Be cautious of any source claiming to sell tesofensine—these products are unregulated and potentially dangerous. If you're interested in weight loss treatment now, we offer FDA-approved options like semaglutide and tirzepatide.
Once available, tesofensine may be particularly suitable for patients who prefer oral medications over injections, those who experience significant GI side effects with GLP-1 therapies, or those who struggle with food cravings and emotional eating (due to its dopamine pathway effects). Our physicians can help determine the best approach for your needs.
Stay Updated
Be the first to know when tesofensine becomes available. In the meantime, our team can discuss FDA-approved options like semaglutide and tirzepatide.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*Tesofensine is an investigational medication that has completed Phase 2 clinical trials with Phase 3 trials ongoing. It is NOT FDA approved for commercial sale. The weight loss figure cited (10.6%) is from a Phase 2 trial at the 1.0mg dose, which The Lancet later flagged with an expression of concern. Tesofensine may increase heart rate and has other cardiovascular considerations under evaluation. Any source claiming to sell tesofensine outside of clinical trials is unregulated and potentially dangerous. BHRC does not currently offer tesofensine. This page is for informational purposes only. Consult with our medical team about FDA-approved weight loss options available today.
